Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Angela Jeong, Kiall Francis Suazo, W. Gibson Wood, Mark D. Distefano & Ling Li. (2018) Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease. Critical Reviews in Biochemistry and Molecular Biology 53:3, pages 279-310.
Read now
Read now
Jing Gu, Zheng Sui, Chunshu Fang & Qunyou Tan. (2017) Stereochemical considerations in pharmacokinetic processes of representative antineoplastic agents. Drug Metabolism Reviews 49:4, pages 438-450.
Read now
Read now
Niklas Feldhahn, Anna Arutyunyan, Sonia Stoddart, Bin Zhang, Sabine Schmidhuber, Sun-Ju Yi, Yong-mi Kim, John Groffen & Nora Heisterkamp. (2012) Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. OncoImmunology 1:5, pages 618-629.
Read now
Read now
A.D. Adema, K. Van Der Born, R.J. Honeywell & G.J. Peters. (2009) Cell Cycle Effects and Increased Adduct Formation by Temozolomide Enhance the Effect of Cytotoxic and Targeted Agents in Lung Cancer Cell Lines. Journal of Chemotherapy 21:3, pages 338-346.
Read now
Read now
Julie A Spicer. (2008) New small-molecule inhibitors of mitogen-activated protein kinase kinase. Expert Opinion on Drug Discovery 3:7, pages 801-817.
Read now
Read now
C Lance Cowey & W Kimryn Rathmell. (2008) Using molecular biology to develop drugs for renal cell carcinoma. Expert Opinion on Drug Discovery 3:3, pages 311-327.
Read now
Read now
Abel D Jarell, Donald Lawrence & Hensin Tsao. (2007) The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. Biologics: Targets and Therapy 1:4, pages 407-414.
Read now
Read now
Thomas Lam, John W. Hetherington, John Greenman, Samantha Little & Anthony Maraveyas. (2007) Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. Acta Oncologica 46:8, pages 1169-1177.
Read now
Read now
Articles from other publishers (32)
Ming-tao Xia, Ling Yu, Zhi-wei Yan, You-de Wang, Li-ying Zhang, Guang-xin Miao & Shuai Li. (2023) FTase inhibitors and cancer: prospects for use in targeted therapies. Medicinal Chemistry Research.
Crossref
Crossref
Subramanian Muthamil, Hyun Yong Kim, Hyun-Jun Jang, Ji-Hyo Lyu, Ung Cheol Shin, Younghoon Go, Seong-Hoon Park, Hee Gu Lee & Jun Hong Park. (2023) Understanding the relationship between cancer associated cachexia and hypoxia-inducible factor-1. Biomedicine & Pharmacotherapy 163, pages 114802.
Crossref
Crossref
Ramona Hartinger, Eva-Maria Lederer, Elisa Schena, Giovanna Lattanzi & Karima Djabali. (2023) Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson–Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies. Cells 12:10, pages 1350.
Crossref
Crossref
Gizem Kursunluoglu, Duygu Erdogan, Elcin Cagatay, Esra Bulut Atalay, Seminay Guler, Yonca Gungor & Hulya Ayar Kayali. 2021. Protein Kinases - Promising Targets for Anticancer Drug Research. Protein Kinases - Promising Targets for Anticancer Drug Research.
Yukari Shirai, Christalle C. T. Chow, Gouki Kambe, Tatsuya Suwa, Minoru Kobayashi, Itsuki Takahashi, Hiroshi Harada & Jin-Min Nam. (2021) An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor. Cancers 13:11, pages 2813.
Crossref
Crossref
Peter Makhov, Ji A. Sohn, Ilya G. Serebriiskii, Rushaniya Fazliyeva, Vladimir Khazak, Yanis Boumber, Robert G. Uzzo & Vladimir M. Kolenko. (2020) CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma. British Journal of Cancer 123:12, pages 1749-1756.
Crossref
Crossref
Dia Advani, Rohan Gupta, Rahul Tripathi, Sudhanshu Sharma, Rashmi K. Ambasta & Pravir Kumar. (2020) Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach. Neurochemistry International 140, pages 104841.
Crossref
Crossref
Jialiang Wang, Huan Wei, Yanlin Huang, Dongmei Chen, Guofen Zeng, Yifan Lian & Yuehua Huang. (2019) The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells. Aging 11:15, pages 5769-5785.
Crossref
Crossref
Seema Shah, Ethan J. Brock, Kyungmin Ji & Raymond R. Mattingly. (2019) Ras and Rap1: A tale of two GTPases. Seminars in Cancer Biology 54, pages 29-39.
Crossref
Crossref
Sarah J. Ross, Alexey S. Revenko, Lyndsey L. HansonRebecca Ellston, Anna StaniszewskaNicky WhalleySanjay K. Pandey, Mitchell RevillClaire RooneyLinda K. Buckett, Stephanie K. Klein, Kevin HudsonBrett P. MoniaMichael ZindaDavid C. BlakeyPaul D. Lyne & A. Robert Macleod. (2017) Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Science Translational Medicine 9:394.
Crossref
Crossref
Bettina Buchmann, Katinka Döhner, Thomas Schirdewahn, Beate Sodeik, Michael P. Manns, Heiner Wedemeyer, Sandra Ciesek & Thomas von Hahn. (2017) A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. Antiviral Research 141, pages 116-123.
Crossref
Crossref
Sarah E. Fenton, Kelli A. Hutchens & Mitchell F. Denning. (2015) Targeting Fyn in Ras-transformed cells induces F-actin to promote adherens junction-mediated cell-cell adhesion. Molecular Carcinogenesis 54:10, pages 1181-1193.
Crossref
Crossref
Leah Ray Strickland, Harish Chandra Pal, Craig A. Elmets & Farrukh Afaq. (2015) Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Letters 359:1, pages 20-35.
Crossref
Crossref
Seung Hyun Oh, Ju-Hee Kang, Jong Kyu Woo, Ok-Hee Lee, Edward S. Kim & Ho-Young Lee. (2012) A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer. International Journal of Cancer 131:3, pages 537-547.
Crossref
Crossref
Xiang Li, Varsha Rao, Jin Jin, Bin Guan, Kenna L. Anderes & Charles J. Bieberich. (2012) Identification and Validation of Inhibitor-Responsive Kinase Substrates Using a New Paradigm To Measure Kinase-Specific Protein Phosphorylation Index. Journal of Proteome Research 11:7, pages 3637-3649.
Crossref
Crossref
Vasiliki A. Nikolaou, Alexander J. Stratigos, Keith T. Flaherty & Hensin Tsao. (2012) Melanoma: New Insights and New Therapies. Journal of Investigative Dermatology 132:3, pages 854-863.
Crossref
Crossref
Elena Sacco, David Metalli, Michela Spinelli, Romilde Manzoni, Maria Samalikova, Rita Grandori, Andrea Morrione, Silvio Traversa, Lilia Alberghina & Marco Vanoni. (2012) Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells. Biotechnology Advances 30:1, pages 233-243.
Crossref
Crossref
John Kauh, Chantal Chanel‐Vos, Daniel Escuin, Michael P. Fanucchi, R. Donald Harvey, Nabil Saba, Dong M. Shin, Anthony Gal, Lin Pan, Michael Kutner, Suresh S. Ramalingam, Laura Bender, Adam Marcus, Paraskevi Giannakakou & Fadlo R. Khuri. (2011) Farnesyl transferase expression determines clinical response to the docetaxel‐lonafarnib combination in patients with advanced malignancies. Cancer 117:17, pages 4049-4059.
Crossref
Crossref
Deviney Chaponis, Jessica W. Barnes, Jamie L. Dellagatta, Santosh Kesari, Eva Fast, Claire Sauvageot, Dipak Panagrahy, Emily R. Greene, Naren Ramakrishna, Patrick Y. Wen, Andrew L. Kung, Charles Stiles & Mark W. Kieran. (2011) Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. Journal of Neuro-Oncology 104:1, pages 179-189.
Crossref
Crossref
Shinji Mizuarai & Hidehito Kotani. (2010) Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Human Genetics 128:6, pages 567-575.
Crossref
Crossref
István Peták, Richárd Schwab, László Őrfi, László Kopper & György Kéri. (2010) Integrating molecular diagnostics into anticancer drug discovery. Nature Reviews Drug Discovery 9:7, pages 523-535.
Crossref
Crossref
Louise A Knight, Christian M Kurbacher, Sharon Glaysher, Augusta Fernando, Ralf Reichelt, Susanne Dexel, Uwe Reinhold & Ian A Cree. (2009) Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay. BMC Cancer 9:1.
Crossref
Crossref
Shozo Yoshida, Naoto Furukawa, Shoji Haruta, Yasuhito Tanase, Seiji Kanayama, Taketoshi Noguchi, Mariko Sakata, Yoshihiko Yamada, Hidekazu Oi & Hiroshi Kobayashi. (2009) Theoretical model of treatment strategies for clear cell carcinoma of the ovary: Focus on perspectives. Cancer Treatment Reviews 35:7, pages 608-615.
Crossref
Crossref
V. Craig Jordan, Joan S. Lewis-Wambi, Roshani R. Patel, Helen Kim & Eric A. Ariazi. (2009) New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. The Breast 18, pages S10-S17.
Crossref
Crossref
Emer O. Hanrahan, Merrill S. Kies, Bonnie S. Glisson, Fadlo R. Khuri, Lei Feng, Hai T. Tran, Lawrence E. Ginsberg, Mylene T. Truong, Waun K. Hong & Edward S. Kim. (2009) A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology 32:3, pages 274-279.
Crossref
Crossref
Thomas L. Hocker, Meena K. Singh & Hensin Tsao. (2008) Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside. Journal of Investigative Dermatology 128:11, pages 2575-2595.
Crossref
Crossref
Lars Möllgård, Stefan Deneberg, Hareth Nahi, Sofia Bengtzen, Kerstin Jonsson-Videsäter, Thoas Fioretos, Anna Andersson, Christer Paul & Sören Lehmann. (2007) The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 62:3, pages 439-448.
Crossref
Crossref
Jessica Plati, Octavian Bucur & Roya Khosravi‐Far. (2008) Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. Journal of Cellular Biochemistry 104:4, pages 1124-1149.
Crossref
Crossref
Myung-Ju Oh, Sun-Ju Yi, Young-Hwa Jeong, Young-Ho Paik & Byung-Hak Jhun. (2008) Effects of Farnesyltransferase Inhibitor Lonafarnib on Insulin Actions. Journal of Life Science 18:5, pages 598-604.
Crossref
Crossref
M. Singh, J. Lin, T.L. Hocker & H. Tsao. (2007) Genetics of melanoma tumorigenesis. British Journal of Dermatology 158:1, pages 15-21.
Crossref
Crossref
Irina Buhaescu & Hassane Izzedine. (2007) Mevalonate pathway: A review of clinical and therapeutical implications. Clinical Biochemistry 40:9-10, pages 575-584.
Crossref
Crossref
D. Stachel, M. Albert & I. Schmid. (2007) Neue Therapieansätze in der pädiatrischen OnkologieNew therapeutic approaches in pediatric oncology. Monatsschrift Kinderheilkunde 155:2, pages 127-133.
Crossref
Crossref